Biochemics sec

Author: ljpd

August undefined, 2024

WebThe relevant facts trace back to the SEC indictment of BioChemics and BioChemics’s CEO John Masiz for securities fraud in 2012. See SEC v. Biochemics, Inc., 435 F. Supp. 3d 281, 285 (D. Mass. 2024) (appeal dismissed as moot at SEC v. Masiz, No. 19-2206, No. 20-1177, No. 20- WebAug 29, 2024 · According to the complaint, when BioChemics finally did conduct one clinical trial, it misrepresented the results of that trial. The complaint further alleged that Masiz …

Biochemistry - Wikipedia

WebJan 17, 2024 · See SEC v. BioChemics, Inc. et al., No. 12-12324-MLW (D. Mass.). On 8/18/18 the Commission dismissed the claims against Masiz under Section 10 (b) of, and … WebLaw360, Boston (October 10, 2024, 5:10 PM EDT) -- After dodging a $17 million payment to the U.S. Securities and Exchange Commission, BioChemics Inc. will have to deal with a court-appointed... philharmonix termine

Biochemics, Inc. v. Axis Reinsurance Co. - casetext.com

WebJan 14, 2014 · Biochemics, Inc. Overview. Biochemics, Inc. filed as a Foreign For-Profit Corporation in the State of Texas on Tuesday, January 14, 2014 and is approximately nine years old, as recorded in documents filed with Texas Secretary of State.A corporate filing is called a foreign filing when an existing corporate entity files in a state other than the state … Webthe SEC served document subpoenas on Biochemics and Masiz in March 2012 (during the policy period); and the SEC filed an enforcement action against Biochemics, Masiz, and two promoters retained by the company in December 2012 (after the expiration of the policy period). Biochemics notified AXIS of the January and March 2012 subpoenas. WebMar 25, 2015 · The judgment entered on March 25, 2015, supplements the March 18, 2015 judgment, and requires BioChemics to disgorge $15,105,325 in ill-gotten gains plus … philharmonix termine 2022

BioChemics, Inc., John Masiz, Craig Medoff and Gregory Kroning – …

Biochemics, Inc. v. Axis Reinsurance Co., 963 F. Supp. 2d 64

WebLaw360, Boston (September 11, 2024, 6:30 PM EDT) -- The U.S. Securities and Exchange Commission and a Massachusetts federal judge appeared skeptical Tuesday of BioChemics Inc.'s claims that it... WebJan 6, 2015 · Plaintiffs BioChemics, Inc., and John Masiz sued defendant Axis Reinsurance Company (“AXIS”) for defense costs arising out of a Securities and Exchange Commission (“SEC”) investigation and enforcement action under their directors and officers (“D & O”) liability insurance policy. philharmony 語源WebDec 14, 2012 · BioChemics of Danvers faces fraud charges By Beth Healy Globe Staff,December 14, 2012, 2:17 p.m. Federal securities regulators on Friday filed civil fraud charges against BioChemics Inc. of... phil harnage

"Web•the SEC served deposition subpoenas on Masiz and two other individuals in January 2012 (during the policy period); • the SEC served document subpoenas on Biochemics and Masiz in March 2012 (during the policy period); and • the SEC filed an enforcement action against Biochemics, Masiz, and two promoters retained by the company in December … " - Biochemics sec

Biochemics sec

SEC v. Biochemics, Inc., et al. Case Number: 12-cv-12324 …

WebCompany profile page for BioChemics Inc including stock price, company news, press releases, executives, board members, and contact information WebDefine biochemics. biochemics synonyms, biochemics pronunciation, biochemics translation, English dictionary definition of biochemics. ... The SEC previously obtained a $17 million judgment against BioChemics and a separate judgment against a promoter of BioChemics stock who wasn't registered as a broker.

Did you know?

WebThe treatment that could produce the money for BioChemics to pay down its SEC debt is already being prescribed by doctors associated with “leading medical institutions,” Schlichtmann said. In addition to the $17.2 million BioChemics owes the SEC, Florida-based private equity firm ADEC Private WebLaw360 (May 11, 2024, 9:54 PM EDT) -- Axis Reinsurance Co. on Thursday urged the First Circuit to uphold a Massachusetts federal judge's ruling that it doesn't have to cover BioChemics Inc.'s...

WebDec 16, 2012 · Three repeat securities law violators teamed up to defraud 70 investors of over $9 million over three years. The complaint claims the defendants sold interests in a privately held biochemical company based on a series of misrepresentations. SEC v. Biochemics, Inc., Civil Action No. 1:12-cv-12324 (D. Mass. Filed Dec. 14, 2012). WebBiochemistry or biological chemistry is the study of chemical processes within and relating to living organisms. A sub-discipline of both chemistry and biology, biochemistry may be divided into three fields: structural …

WebDec 17, 2012 · Courthouse News Staff / December 17, 2012. BOSTON (CN) - An attorney duped investors for $9 million through his purported biopharma company, Biochemics, … WebFeb 3, 2015 · § the SEC served document subpoenas on Biochemics and Masiz in March 2012 (during the policy period); and § the SEC filed an enforcement action against Biochemics, Masiz, and two promoters...

WebThe SEC claimed in a 2012 lawsuit that BioChemics and Masiz lied about the status of topical gels that would allow medicine to be absorbed through the skin. They allegedly falsely asserted the...

WebMar 4, 2024 · biochemistry, study of the chemical substances and processes that occur in plants, animals, and microorganisms and of the changes they undergo during … philharmonix the vienna berlin music clubWebDec 14, 2012 · SEC Charges Massachusetts Company, CEO and Promoters With $9 Million Securities Fraud Recently, the Securities and Exchange Commission filed an enforcement action in federal court in Boston against BioChemics, Inc., a biopharmaceutical company based in Danvers, Massachusetts, its CEO and two individuals it paid to solicit investors. phil harmsWebSep 6, 2024 · In Biochemics, Inc. v. AXIS Reinsurance Company, 2024 WL 2223125 (1st Cir. 2024), the SEC issued a subpoena to Biochemics on May 5, 2011, requesting that Biochemics produce certain documentation in connection with the SEC’s investigation into whether Biochemics and its President and CEO, John Masiz, had committed securities … phil harms facebookWebDec 16, 2012 · The SEC claims that in 2010 and 2011 BioChemics, Masiz, and Kroning misrepresented to investors and potential investors the status of research collaborations with other pharmaceutical companies: “For example, in 2010 and 2011, BioChemics published a multiple-page overview entitled Executive Summary (“Executive Summary”) that touted … phil harmon ufWebIn 2015, the SEC won a $17.2 million judgment against BioChemics stemming from an allegation that BioChemics misled 70 investors by exaggerating the positive test results … phil harnby phil haroldWebBiochemists work in industries like agriculture, medical research, biotechnology and nutritional research. Our students go on to positions in research and industry, as well as graduate study in biochemistry, … phil harper as harry nile